Jasper Therapeutics to Present Data on Briquilimab in Mast
globenewswire.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from globenewswire.com Daily Mail and Mail on Sunday newspapers.
Jasper Therapeutics to Present Data on Briquilimab in Mast Cell Driven Diseases at the EAACI Congress 2024
tmcnet.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from tmcnet.com Daily Mail and Mail on Sunday newspapers.
Buckinghamshire Junior Doctor wins prestigious national award for ground-breaking research into pancreatic cancer
buckshealthcare.nhs.uk - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from buckshealthcare.nhs.uk Daily Mail and Mail on Sunday newspapers.
Breast cancer affects more than one million women per year worldwide. Through this study, we develop a nanoparticle-based drug delivery system to target breast cancer cells. Aspirin has been found to inhibit thromboembolic diseases with its tumor-preventing activity. As a consequence, it relieves disease symptoms and severity. Here, mesoporous Silica Nanoparticles (MNP) have been used to deliver Aspirin to the tumor location. MNP-based Aspirin in folic acid (F)-conjugated Polydopamine (MNP-Asp-PD-PG-F) vehicles are prepared for targeted breast cancer therapy. The vehicle hinges on MNP altered with polymer polyethylene glycol (PG), polydopamine (PD), and folic acid (F). The delivery vehicle was studied for in vitro drug release, cytotoxicity and breast cancer cell proliferation. Folic Acid-conjugated drug delivery vehicles let MNPs achieve an elevated targeting efficacy, ideal for cancer therapy. It was also observed that compared to free Aspirin, our drug delivery system (MNP-Asp-PD-PG